Papers, abstracts, presentations, posters and webcasts emanating from the registry
Webcast
ATTD 2024 Robert Ryder, Mahender Yadagiri, Lynne Munro, Harry Frydenberg, Sigal Fishman, Erwin Santo, Tadej Battelino, Primoz Kotnik, James Byrne, Julian Teare, Charlotte De Jonge, Jan Greve, Jessica Mcmaster, Jacob Chisholm, Lilian Kow, John Mason, Ricardo Cohen, Ju ̈rgen Stein, Piya Sen Gupta. DJBL treatment for Type 2 Diabetes and Obesity: 9 vs 12 month implantation in a worldwide registry.
Webcast: https://www.youtube.com/watch?v=5vWTDITAGKg
EASD 2023 R.E.J. Ryder, J. Stein, T. Battelino, J. Teare, A. Ruban, H. Frydenberg, L. Munro, S. Fishman, R. Cohen, C. de Jonge, J.-W. Greve, H. Sourij, P. Sen Gupta, K. Laubner, J. Seufert. Duodenal jejunal bypass liner (DJBL) treatment for type 2 diabetes and obesity: glycaemic and CVD risk factor improvements among 1068 patients treated worldwide.
Webcast: https://www.youtube.com/watch?v=7zqDOmI5cU4
DUK 2023 REJ Ryder, M Yadagiri, W Burbridge, SP Irwin, T Bashir, RA Allden, JP Bleasdale, EN Fogden, M Anderson, P Sen Gupta. EndoBarrier treatment for longstanding Type 2 diabetes and obesity: A comparison of outcomes with an implantation period of 9 months versus 12 months implantation in 90 consecutive Endobarrier treated patients.
Webcast: https://youtu.be/uvnJzoMJZfw
EASD 2022 R.E.J. Ryder, P. Sen Gupta, T. Battelino, P. Kotnik, J. Teare, A. Rubin, H. Frydenberg, L. Munro, S. Fishman, R. Cohen, C. de Jonge, J.-W. Greve, H. Sourij, K. Laubner, J. Duodenal jejunal bypass liner (DJBL) treatment for type 2 diabetes and obesity: glycaemic and CVD risk factor improvements vs risks in patients treated worldwide.
Webcast: https://www.easd.org/media-centre/home.html#!resources/duodenal-jejunal….
EASD 2021 R.E.J. Ryder, P. Sen Gupta, R. Stengel, K. Mitchell, R. Drummond, H. Frydenberg, L. Munro, S. Fishman, R. Cohen, C. de Jonge, J. Greve, M. Benes, J. Aberle, K. Laubner, J. Seufert. Duodenal jejunal bypass liner (DJBL) for treatment of type 2 diabetes and obesity: risks and benefits among 926 patients in the worldwide EndoBarrier (EB) registry.
Webcast: https://www.easd.org/media-centre/home.html#!resources/b-duodenal-jejun…
DUK 2021, Annual Professional Conference (Virtual Meeting). REJ Ryder, P Sen Gupta, SP Irwin, W Burbridge, MC Wyres, T Bashir, H Gandhi, RA Allden, JP Bleasdale, EN Fogden, M Anderson, M Yadagiri. EndoBarrier treatment for longstanding type 2 diabetes and obesity: outcomes one year after EndoBarrier in 90 consecutively treated patients.
Webcast: https://youtu.be/WGU825T7yxE
EASD 2020 R.E.J. Ryder, M. Yadagiri, S.P. Irwin, W. Burbridge, M.C. Wyres, R. Allden, T. Bashir, J.P. Bleasdale, P. Sen Gupta, E.N. Fogden, M.P. Anderson. UK 1st National Health Service (NHS) EndoBarrier service for uncontrolled diabesity: 2-year outcomes for all 62 treated patients.
Webcast: https://www.easd.org/media-centre/home.html#!resources/uk-1st-national-health-service-nhs-endobarrier-service-for-uncontrolled-diabesity-2-year-outcomes-for-all-62-treated-patients-d0da453a-f0de-41f8-909d-5678bc29b4cb
EASD 2018 An interview with Dr Bob Ryder by Vivienne Parry on behalf of EASD.
Webcast: EASD 2018 - Interview with Dr. Bob Ryder (https://www.youtube.com/watch?v=tHVsJPtnAkY)
EASD 2018 EN Fogden, P Sen Gupta, M Yadagiri, SP Irwin, W Burbridge, T Bashir, RA Allden, JP Bleasdale, MR Anderson and REJ Ryder. Webcast by Dr Bob Ryder presenting his ePoster at the EASD in Berlin, September 2018: Impact of proximal intestinal exclusion with EndoBarrier on key metabolic parameters and cardiovascular risk (UKPDS risk engine) in the first NHS-UK EndoBarrier service.
Webcast: https://www.easd.org/media-centre/home.html#!resources/impact-of-proximal-intestinal-exclusion-with-endobarrier-on-key-metabolic-parameters-and-cardiovascular-risk-ukpds-risk-engine-in-the-first-nhs-uk-endobarrier-service
2023 Robert E.J. Ryder, Katharina Laubner, Marek Benes, Martin Haluzik, Lynne Munro, Harry Frydenberg, Julian P. Teare, Aruchana Ruban, Sigal Fishman, Erwin Santo, Rainer Stengel, Charlotte De Jonge, Jan W. Greve, Ricardo V. Cohen, Cristina M. Aboud, Gerald J. Holtmann, Graeme Rich, Jess J. McMaster, Tadej Battelino,Primoz Kotnik, James P. Byrne, John C. Mason, Justin Bessell, Jeanine Bascomb,21 Lillian Kow, Janes Collins, Jacob Chisholm, Peter N. Pferschy, Harald Sourij, Melissa L. Cull, Melanie C. Wyres, Russell Drummond, Barbara McGowan, Stephanie A. Amiel, Mahi Yadagiri, Piya Sen Gupta, Jens Aberle, and Jochen Seufert. Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide. Diabetes Care dc221952, 30 January 2023
DOI: https://doi.org/10.2337/dc22-1952
Click here for PDF: https://diabetesjournals.org/care/article-pdf/doi/10.2337/dc22-1952/697…
2022 Robert EJ Ryder, Mahi Yadagiri, Wyn Burbridge, Susan P Irwin, Hardeep Gandhi, Tahira Bashir, Rachael A Allden, Melanie Wyres, Melissa Cull, John P Bleasdale, Edward N Fogden, Mark R Anderson, Piya Sen Gupta. Duodenal-jejunal bypass liner for treatment of T2DM and obesity: 4-year outcomes in the first National Health Service (NHS) EndoBarrier service. The British Journal of Diabetes, Volume 22 Issue 2, l December 2022 British Journal of Diabetes 2022;22, P82-86
DOI: https://doi.org/10.15277/bjd.2022.351
Click here for PDF: https://bjd-abcd.com/index.php/bjd/article/view/973/1201
2022 Robert E. J. Ryder, Mahi Yadagiri, Wyn Burbridge, Susan P. Irwin, Hardeep Gandhi, Tahira Bashir, Rachael A. Allden, Melanie Wyres, Melissa Cull, John P. Bleasdale, Edward N. Fogden, Mark R. Anderson, Piya Sen Gupta. Duodenal-jejunal bypass liner for the treatment of type 2 diabetes and obesity: 3-year outcomes in the First National Health Service (NHS) EndoBarrier Service. Diabetic Medicine. 2022;39:e14827
DOI: https://doi.org/10.1111/dme.14827
Click here for PDF:https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.14827
2022 Robert EJ Ryder, Mahi Yadagiri, Wyn Burbridge, Susan P Irwin, Hardeep Gandhi, Tahira Bashir, Rachael A Allden, Melanie Wyres, Melissa Cull, John P Bleasdale, Edward N Fogden, Mark R Anderson, Piya Sen Gupta. EndoBarrier treatment for longstanding type 2 diabetes and obesity: outcomes one year after EndoBarrier in 90 consecutively treated patients. Practical Diabetes, Volume 39, Issue 3 May/June 2022, P13-16a.
DOI: https://doi.org/10.1002/pdi.2393
Click here for PDF: https://wchh.onlinelibrary.wiley.com/doi/epdf/10.1002/pdi.2393
2021 Robert E R, Piya S G, Mahi Y, Susan P I, Wyn B, et al. Improvement in Renal Function in Participants in the First UK
National Health Service (NHS) EndoBarrier Service for Uncontrolled Diabesity. Current Research Diabetes & Obesity J 2021; 15(1): 555902.
DOI: 10.19080/CRDOJ.2021.15.555902
Click here for PDF: https://juniperpublishers.com/crdoj/pdf/CRDOJ.MS.ID.555902.pdf
2021 Robert EJ Ryder, Mahi Yadagiri, Wyn Burbridge, Susan P Irwin, Hardeep Gandhi, Tahira Bashir, Rachael A Allden, Melanie Wyres, Melissa Cull, John P Bleasdale, Edward N Fogden, Mark R Anderson, Piya Sen Gupta. The United Kingdom’s first NHS EndoBarrier service for long-standing poorly controlled type 2 diabetes and obesity: outcomes one year after EndoBarrier removal. The British Journal of Diabetes, Volume 21 Issue 1, l June 2021, P76-83,
DOI: https://doi.org/10.15277/bjd.2021.295
Click here for PDF: https://bjd-abcd.com/index.php/bjd/article/view/733/963
2019 Robert EJ Ryder, Susan P Irwin, Wyn Burbridge, Hardeep Gandhi, Tahira Bashir, Rachael A Allden, Mordel Wilson, Melanie Wyres, Melissa Cull, Mahi Yadagiri, John P Bleasdale, Edward N Fogden, Mark R Anderson, Piya Sen Gupta. The United Kingdom's first NHS Endobarrier service for advanced diabesity: 1-year outcomes for all 62 treated patients. The British Journal of Diabetes, Volume 19 Issue 2, l December 2019, P110-117
DOI: https://doi.org/10.15277/bjd.2019.226
Click here for PDF: https://bjd-abcd.com/index.php/bjd/article/view/479/685
2018 Robert EJ Ryder, Mahi Yadagiri, Susan P Irwin, Wyn Burbridge, Hardeep Gandhi, Rachael A Allden, John P Bleasdale, Edward N Fogden, Mark R Anderson, Piya Sen Gupta. Maintenance of efficacy after duodenal–jejunal bypass liner explantation in the first NHS EndoBarrier service. The British Journal of Diabetes, Volume 18 Issue 1, l January/February/March 2018, P14-17
DOI: https://doi.org/10.15277/bjd.2017.157
Click here for PDF: https://bjd-abcd.com/index.php/bjd/article/view/242/464
DUK 2024 REJ Ryder, M Yadagiri, W Burbridge, SP Irwin, T Bashir, RA Allden, JP Bleasdale, EN Fogden, MR Anderson, P Sen Gupta. EndoBarrier treatment for longstanding type 2 diabetes and obesity: Outcomes 2 years after EndoBarrier in 90 consecutively treated patients. Diabetic Medicine, Abstracts of the Diabetes UK Professional Conference 2024, ExCeL London, 17‐19 April 2024. P245 (P143).
https://doi.org/10.1111/dme.15296
https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.15296
ATTD 2024 Robert Ryder, Mahender Yadagiri, Lynne Munro, Harry Frydenberg, Sigal Fishman, Erwin Santo, Tadej Battelino, Primoz Kotnik, James Byrne, Julian Teare, Charlotte De Jonge, Jan Greve, Jessica Mcmaster, Jacob Chisholm, Lilian Kow, John Mason, Ricardo Cohen, Ju ̈rgen Stein, Piya Sen Gupta. Endoscopic Duodenal-Jejunal Bypass Liner (DJBL) Treatment for Type 2 Diabetes and Obesity: Comparing 9 vs 12 Month implantation in a Worldwide Registry. O055 / #438 Oral Presentations 07, Diabetes Technology & Therapeutics Volume 26, Issue s2 February 2024. Abstract 438, page A-68.
https://doi.org/10.1089/dia.2024.2525.abstracts
EASD 2023 R.E.J. Ryder, J. Stein, T. Battelino, J. Teare, A. Ruban, H. Frydenberg, L. Munro, S. Fishman, R. Cohen, C. de Jonge, J.-W. Greve, H. Sourij, P. Sen Gupta1, K. Laubner, J. Seufert. Duodenal Jejunal Bypass Liner (DJBL) treatment for type 2 diabetes and obesity: glycaemic and CVD risk factor improvements vs risks among 1068 patients treated worldwide . Diabetologia volume 66, pages1–536 (2023), Abstract 727.
Link to Abstract: scroll to abstract 727 https://link.springer.com/article/10.1007/s00125-023-05969-6#Sec112
ADA 2023 REJ Ryder, M Yadagiri, L Munro, H Frydenberg, S Fishman, JP Byrne, JP Teare, C De Jonge, JW Greve, JJ McMaster, J Chisholm, L Kow, JC Mason, J Stein, RV Cohen, P Sen Gupta. Comparing 9- vs 12-Month Implantation in the Worldwide EndoBarrier (EB) Registry.
Abstract: https://abcd.care/sites/default/files/resources/ADA_San_Diego_2023_Endo…
ePoster: https://youtu.be/8vv3VMHzzu4
ADA 2022 Robert E.J. Ryder, Piya Sen Gupta, Mahender Yadagiri, Winnifred (Wyn) Burbridge, Susan P. Irwin, Tahira Bashir, Hardeep Gandhi, Melanie C. Wyres, Racheal Allden, John Bleasdale, Edward Fogden, Mark Anderson. UK 1st National Health Service (NHS) Endobarrier (EB) Service For Uncontrolled Diabesity: 4-year Outcomes For All 62 Treated Patients.
https://doi.org/10.2337/db22-1416-P
ADA 2022 Robert E.J. Ryder, Julian P. Teare, Aruchuna Ruban, Martin Haluzik, Lynne Munro, Harry Frydenberg, Jessica J. McMaster, Sigal Fishman, Rainer Stengel, Ricardo V. Cohen, Cristina M. Aboud, James P. Byrne, Gerald J. Holtman, Charlotte De Jonge, Jan Willem Greve, John C. Mason, Justin Bessell, Lilian Kow, Harald Sourij, Peter N. Pferschy, JR., Melissa L. Cull, Melanie C. Wyres, Russell Drummond, Barbara McGowan, Stephanie A. Amiel, Mahender Yadagiri, Piya Sen Gupta, Katharina Laubner, Jochen Seufert. Risk Benefit Data from the Worldwide EndoBarrier (EB) Registry. Diabetes 2022;71(Supplement_1):1415-P
https://doi.org/10.2337/db22-1415-P
ATTD 2022 R. Ryder, M. Yadagiri, W. Burbridge, S. Irwin, H. Gandhi, T. Bashir, R. Allden, M. Wyres, M. Cull, J. Bleasdale, E. Fogden, M. Anderson, P. Sen Gupta. Duodenal-Jejunal Bypass Liner For Treatment Of Type 2 Diabetes And Obesity: Four Year Outcomes In The First National Health Service (NHS) Endobarrier Service. Diabetes Technology & Therapeutics Volume 24, Supplement 1, 2022. Abstract 201, page A-191
https://www.liebertpub.com/doi/epdf/10.1089/dia.2022.2525.abstracts
EASD 2022 R.E.J. Ryder, P. Sen Gupta, T. Battelino, P. Kotnik, J. Teare, A. Rubin, H. Frydenberg, L. Munro, S. Fishman, R. Cohen, C. de Jonge, J.-W. Greve, H. Sourij, K. Laubner, J. Duodenal jejunal bypass liner (DJBL) treatment for type 2 diabetes and obesity: glycaemic and CVD risk factor improvements vs risks in patients treated worldwide.
Abstract: https://www.easd.org/media-centre/home.html#!resources/duodenal-jejunal…
ADA 2021 Robert E.J. Ryder, Piya Sen Gupta, Mahender Yadagiri, Wyn Burbridge, Susan P. Irwin, Tahira Bashir, Melanie C. Wyres, John Bleasdale, Mark Anderson, Edward Fogden. UK 1st National Health Service (NHS) Endobarrier (EB) Service for Uncontrolled Diabesity: 3-year Outcomes for All 62 Treated Patients. Diabetes 2022;71(Supplement_1):1416-P
https://doi.org/10.2337/db22-1416-P
EASD 2021 R.E.J. Ryder, P. Sen Gupta, R. Stengel, K. Mitchell, R. Drummond, H. Frydenberg, L. Munro, S. Fishman, R. Cohen, C. de Jonge, J. Greve, M. Benes, J. Aberle, K. Laubner, J. Seufert. Duodenal jejunal bypass liner (DJBL) for treatment of type 2 diabetes and obesity: risks and benefits among 926 patients in the worldwide EndoBarrier (EB) registry.
Abstract: https://www.easd.org/media-centre/home.html#!resources/b-duodenal-jejun…
DUK 2021 Dr R.E.J Ryder, Dr P. Sen Gupta, W Burbridge, S.P. Irwin, T. Bashir, R.A. Allden, J.P. Bleasdale, E.N. Fogden, M.R. Anderson, M. Yadagiri. EndoBarrier treatment for longstanding type 2 diabetes and obesity: Outcomes one-year after EndoBarrier in 90 consecutively treated patients. Diabetic Medicine, New technology, therapies and treatment. P222
https://doi.org/10.1111/dme.43_14556
Link to Abstract PDF: https://abcd.care/sites/default/files/resources/Ryder_DUK_2021_EndoBarr…
ADA 2020 Robert E.J. Ryder, Mahender Yadagiri, Susan P. Irwin, Wyn Burbridge, Melanie C. Wyres, Tahira Bashir, Hardeep Gandhi, Rachael Allden, John Bleasdale, Edward Fogden, Mark Anderson, Piya Sen Gupta. UK 1st National Health Service (NHS) EndoBarrier (EB) Service For Uncontrolled Diabesity: 2-year Outcomes For All 62 Treated Patients. Diabetes 2020;69(Supplement_1):76-OR
https://doi.org/10.2337/db20-76-OR
ADA 2020 Robert E.J. Ryder, Mahender Yadagiri, Susan P. Irwin, Wyn Burbridge, Rachael Allden, Tahira Bashir, John Bleasdale, Edward Fogden, Mark Anderson, Piya Sen Gupta, Paul Cockwell. Improvement In Renal Function Associated With EndoBarrier (EB) Induced Weight Loss. Diabetes 2020;69(Supplement_1):2009-P
https://doi.org/10.2337/db20-2009-P
EASD 2020 R.E.J. Ryder, M. Yadagiri, S.P. Irwin, W. Burbridge, M.C. Wyres, R. Allden, T. Bashir, J.P. Bleasdale, P. Sen Gupta, E.N. Fogden, M.P. Anderson. UK 1st National Health Service (NHS) EndoBarrier service for uncontrolled diabesity: 2-year outcomes for all 62 treated patients.
Abstract: https://www.easd.org/media-centre/home.html#!resources/uk-1st-national-…
ADA 2020 Mahender Yadagiri, Fiona Y. Kinney, Natalie Ashman, Jessica Adams, Melanie C. Wyres, Emma S. Sharratt, Cheryl Greenwood, Michael H. Lang, John Bleasdale, Edward Fogden, Mark Anderson, Christopher Walton, Michael A. Greenstone, Robert E. Ryder Endobarrier(EB) In Diabetes/Prediabetes With Obstructive Sleep Apnoea(OSA) Study- The Final Results. Diabetes 2020;69(Supplement_1):2015-P
https://doi.org/10.2337/db20-2015-P
EASD 2020 M. Yadagiri, F.Y. Kinney, N. Ashman, J. Adams, M.C. Wyres, E.S. Sharratt, C. Greenwood, M.H. Lang, J. Bleasdale, E. Fogden, M. Anderson, C. Walton, M.A. Greenstone, R.E.J. Ryder.
Endobarrier in diabetes/prediabetes with obstructive sleep apnoea study: the final results. Diabetologia 63 (Suppl 1), (2020). Abstract 725 on page 350.
https://doi.org/10.1007/s00125-020-05221-5
DUK 2020 Renal REJ Ryder, P Sen Gupta, M Yadagiri, SP Irwin, W Burbridge, RA Allden, JP Bleasdale, EN Fogden, MR Anderson, P Cockwell. Improvement in renal function in chronic kidney disease in the first UK National Health Service (NHS) EndoBarrier Service for uncontrolled diabesity. Diabetic Medicine, New technology, therapies and treatment. P389
https://doi.org/10.1111/dme.44_14245
DUK 2020 REJ Ryder, M Yadagiri, SP Irwin, W Burbridge, T Bashir, RA Allden, JP Bleasdale, EN Fogden, MR Anderson, P Sen Gupta. UK first NHS EndoBarrier service for advanced type 2 diabetes and obesity: Outcomes in all patients six months after device explant. Diabetic Medicine, New technology, therapies and treatment. A29 (P390)
Abstract: https://doi.org/10.1111/dme.5_14244
ePoster: https://doi.org/10.1111/dme.44_14245
EASD 2019 J. Seufert, J. Aberle, H. Frydenberg, L. Munro, S. Fishman, R. Cohen, G. Holtmann, C. de Jonge, J. Greve, L. Kow, J. Bessell, H. Sourij, M. Benes, R.E.J. Ryder. Duodenal jejunal bypass liner (DJBL) for treatment of type 2 diabetes and obesity - the risk benefit ratio from the worldwide EndoBarrier (EB) registry in 871 patients.
Abstract: https://www.easd.org/media-centre/home.html#!resources/duodenal-jejunal…
DUK Liverpool 2019 REJ Ryder , M Yadagiri , SP Irwin , W Burbridge , T Bashir , RA Allden , JP Bleasdale , EN Fogden , MR Anderson and P Sen Gupta. UK first National Health Service (NHS) EndoBarrier service for advanced Type 2 diabetes and obesity: One year outcomes in all patients treated. Diabetic Medicine 2019. 36 (Suppl 1): Abstract A2. (P352)
https://doi.org/10.1111/dme.13882
DUK Liverpool 2019 M Yadagiri, F Kinney, J Adams, A Mohammed, JP Bleasdale, EN Fogden, MR Anderson, M Greenstone, C Walton and REJ Ryder. One year results of Association of British Clinical Diabetologists (ABCD) EndoBarrier in Type 2 diabetes/prediabetes with obstructive sleep apnoea study. Diabetic Medicine 2019. 36 (Suppl 1): Abstract P356.
https://doi.org/10.1111/dme.40_13883
ABCD Spring 2019 REJ Ryder, P Sen Gupta, M Yadagiri, SP Irwin, W Burbridge, T Bashir, RA Allden, JP Bleasdale, EN Fogden, M Anderson and P Cockwell. Improvement in renal function in the first UK NHS EndoBarrier service for uncontrolled diabesity. Poster, ABCD Spring Meeting 2019. Br J Diabetes 2019;19:152-155 THE BRITISH JOURNAL OF DIABETES 152
http://dx.doi.org/10.15277/bjd.2019.234
WCITD 2019a P Sen Gupta, BM McGowan, RS Drummond, SA Amiel and REJ Ryder. Evaluation of the efficacy and safety of endoscopically achieved proximal intestinal exclusion as an adjunct to glucagon-likepeptide-1 therapy in diabesity: REVISE-Diabesity clinical trial. Proceedings of 4th World Congress on Interventional Therapies for Type 2 Diabetes, April 2019.
https://abcd.care/resource/wcitd2019reviseabstractsubmissionconfirmation
WCITD 2019b REJ Ryder, M Yadagiri, SP Irwin, W Burbridge, T Bashir, MC Wyres, ML Cull, JP Bleasdale, RA Allden, EN Fogden, M Anderson and P Sen Gupta. UK first National Health Service (NHS) Endobarrier Service for uncontrolled DIABESITY shows the metabolic improvements 6-months after Endobarrier removal are well maintained. Proceedings of 4th World Congress on Interventional Therapies for Type 2 Diabetes, April 2019.
https://abcd.care/resource/wcitd2019nhsebabstractfinal
WCITD 2019c M Yadagiri, F Kinney, J Adams, N. Ashman, JP Bleasdale, EN Fogden, MR Anderson, M Greenstone, C Walton, REJ Ryder. Impact of Endobarrier on need for continuous-positive-airway-pressure ventilation (CPAP) in diabetes/pre-diabetes with obstructive sleep apnoea (OSA) study: current data at Endobarrier removal and 6-months later. Proceedings of 4th World Congress on Interventional Therapies for Type 2 Diabetes, April 2019.
https://abcd.care/resource/wcitd2019endosaabstractsubmissionconfirmation
WCITD 2019d B. Ryder, M. Lynne, H. Frydenberg, S. Fishman, R. Cohen, C. de Jonge, J. Greve, J. Bascomb, J. Bessell, J. McMaster, G. Holtman, G. Rich, J. Collins, L. Kow, P. Pferschy, H. Sourij, J. Byrne, J. Mason, J. Teare, M. Benes. Duodenal Jejunal bypass liner for DIABESITY – Risk versus benefit data from the Association of British Clinical DIiabetologists (ABCD) worldwide Endobarrier Registry. Proceedings of 4th World Congress on Interventional Therapies for Type 2 Diabetes, April 2019.
https://abcd.care/resource/wcitd2019ebregistry
ADA San Fransico 2019a Robert E.J. Ryder, Piya Sen Gupta, Mahender YadagiriI, Susan P. Irwin, Wyn Burbridge, Tahira Bashir, Melanie C. Wyres, Rachael Allden, John Bleasdale, Edward Fogden and Mark Andersoj. UK First National Health Service (NHS) Endobarrier (EB) Service: Maintenance of Improvement One Year after Device Removal. Diabetes 2019 Jun; 68 (Supplement 1): 2047-P.
https://doi.org/10.2337/db19-2047-P
ADA San Fransisco 2019b Mahender Yadagiri, Fiona Y. Kinney, Natalie Ashman, Emma S. Sharratt, Cheryl Greenwood, Jessica Adams, Melanie C. Wyres, Michael H. Lang, John Bleasdale, Edward Fogden, Mark Anderson, Christopher Walton, Michael A. Greenstone and Robert E. Ryder. Endobarrier (EB) in Diabetes/Prediabetes with Obstructive Sleep Apnea (OSA) Study—Maintenance of Improvement after EB Removal. Diabetes 2019 Jun; 68 (Supplement 1): 2080-P.
https://doi.org/10.2337/db19-2080-P
DUK 2018 REJ Ryder, M Yadagiri, SP Irwin, W Burbridge, H Gandhi, RA Allden, JP Bleasdale, EN Fogden, MR Anderson and P Sen Gupta. UK’s first NHS Endobarrier service for diabesity: Outcomes in the first 30 patients to reach six months after explanation of the device. Diabetic Medicine 2018. 35 (Suppl 1): Abstract P416.
https://doi.org/10.1111/dme.48_13571
DUK 2018 M Yadagiri, N Ashman, F Kinney, M Lang, JP Bleasdale, EN Fogden, MR Anderson, M Greenstone, C Walton and REJ Ryder. Preliminary results of the Association of British Clinical Diabetologists sponsored Endobarrier in Type 2 diabetes/prediabetes with obstructive sleep apnoea study. Diabetic Medicine 2018. 35 (Suppl 1): Abstract P418.
https://doi.org/10.1111/dme.48_13571
DUK 2018 S Armstrong, P Sen Gupta, SA Amiel, RS Drummond, BM McGowan, REJ Ryder and MW Pennington. A UK cost-effectiveness analysis of the Endobarrier device in patients with Type 2 diabetes and obesity. Diabetic Medicine 2018. 35 (Suppl 1): Abstract P425.
https://doi.org/10.1111/dme.48_13571
ABCD Spring 2018 Drummond RS, Timmons J, Talla M, Sen Gupta P, Ryder REJ. Liver Abscess secondary to a duodenal-jejunal bypass liner (DJBL) successfully treated with antibiotics but without removal of the device. Poster, ABCD Spring Meeting 2018.
https://bjd-abcd.com/index.php/bjd/article/download/285/538
ADA 2018a Robert E.J. Ryder, Mahender Yadagiri, Susan P. Irwin, Wyn Burbridge, Melanie C. Wyres, Hardeep Gandhi, Melissa L. Cull, Rachel Allden, John Bleasdale, Edward Fogden, Mark Anderson and Piya Sen Gupta. U.K. First National Health Service (NHS) Endobarrier (EB) Service—Outcomes in First 38 Patients to Reach Six Months after Device Explant. Diabetes 2018 Jul; 67 (Supplement 1): 2087-P.
https://doi.org/10.2337/db18-2087-P
ADA 2018b Mahender Yadagiri, Fiona Y. Kinney, Natalie Ashman, Michael H. Lang, Edward Fogden, Mark Anderson, John Bleasdale, Christopher Walton, Michael A. Greenstone and Robert E. Ryder. Endobarrier (EB) in Type 2 Diabetes/Prediabetes with Obstructive Sleep Apnea Study—Preliminary Results. Diabetes 2018 Jul; 67 (Supplement 1): 2071-P.
https://doi.org/10.2337/db18-2071-P
ADA 2018c Robert E.J. Ryder, Lynne Munro, Jessica J. McMaster, Justin Bessell, Jeanine M. Bascomb, Jane E. Collins, Lilian Kow, Jacob Chisholm, Harold Sourij, Peter N. Pferschy, Julian P. Teare, John C. Mason, James P. Byrne, Melanie C. Wyres, Melissa L. Cull, Wyn Burbridge, Susan P. Irwin, Mahender Yadagiri, Edward Fogden,Mark Anderson, Piya Sen Gupta and Marek Benes. First Risk–Benefit Data from the Worldwide Endobarrier Registry. Diabetes 2018 Jul; 67 (Supplement 1): 2097-P.
https://doi.org/10.2337/db18-2097-P
ADA 2018d Piya Sen Gupta, Stephanie Armstrong, Srephanie A. Amiel, Robert E. Ryder and Mark W. Pennington. Cost-Effectiveness Analysis of the EndoBarrier Device in Patients with Type 2 Diabetes. Diabetes 2018 Jul; 67 (Supplement 1): 1250-P.
https://doi.org/10.2337/db18-1250-P
EASD Berlin 2018 EN Fogden, P Sen Gupta, M Yadagiri, SP Irwin, W Burbridge, T Bashir, RA Allden, JP Bleasdale, MR Anderson and REJ Ryder. Impact of proximal intestinal exclusion with EndoBarrier on key metabolic parameters and cardiovascular risk (UKPDS risk engine) in the first NHS-UK EndoBarrier service. Diabetologia 2018, Vol.61 Supplement1: Abstract 711.
https://www.easd.org/media-centre/home.html#!resources/impact-of-proxim…
DUK Manchester 2017 P Sen Gupta, M Yadagiri, SP Irwin, W Burbridge, H Gandhi, RA Allden, JP Bleasdale, EN Fogden, MR Anderson and REJ Ryder. One year efficacy, safety and tolerability outcomes of endoscopic proximal intestinal exclusion therapy using the Endobarrier device: institution of the UK's first National Health Service Endobarrier service for Type 2 diabetes and obesity. Diabetic Medicine 2017. 34 (Suppl 1): Abstract A26.
https://doi.org/10.1111/dme.4_13303
DUK Manchester 2017 M Yadagiri, MH Lang, AAS Mohamed, N Nathani, AB Rajasekaran, JP Bleasdale, EN Fogden, MR Anderson, PS Gupta and REJ Ryder. Endoscopic proximal intestinal exclusion with Endobarrier bringing simultaneous benefit to both diabesity and obstructive sleep apnoea (OSA) requiring overnight continuous positive airway pressure ventilation (CPAP): three case reports. Diabetic Medicine 2017. 34 (Suppl 1): Abstract P224.
https://doi.org/10.1111/dme.19_13304
DUK Manchester 2017 P Sen Gupta, RS Drummond, BM McGowan, B Hayee, T Dew, RP Vincent, CW le Roux, JJ Holst, SA Amiel and REJ Ryder. The interaction o endoscopic proximal intestinal exclusion therapy using Endobarrier with glucagon‐like peptide‐1 (GLP‐1) therapy rapidly improves Type 2 diabetes by increasing fasting and postprandial satiety. Diabetic Medicine 2017. 34 (Suppl 1): Abstract P423.
https://doi.org/10.1111/dme.37_13304
ADA San Diego 2017 Robert E.J. Ryder, Mahender Yadagiri, John P. Bleasdale, Edward N. Fogden, Mark R. Anderson, Piya Sen Gupta. Maintenance of Efficacy after Endobarrier in UK First National Health Service (NHS) Endobarrier Service. Diabetes 2017 Jul; 66 (Supplement 1): 2110-P.
https://ada.scientificposters.com/epsAbstractADA.cfm?id=1
EASD Lisbon 2017a A. Basu, P. Sen Gupta, M. Yadagiri, B.M. McGowan, R.S.Drummond, T.H. Jones, S.A. Amiels, R.E.J, Ryder. Endoscopic proximal intestinal exclusion with Endobarrier therapy is associated with improvement in gonadal function in obese men with diabetes. Diabetologia 2017, Vol.60 Supplement1: Abstract 858.
Abstract: https://www.easd.org/media-centre/home.html#!resources/endoscopic-proxi…
ePoster: https://www.easd.org/media-centre/home.html#!resources/endoscopic-proxi…
EASD Lisbon 2017b REJ Ryder, M Yadagiri, SP Irwin, W Burbridge, H Gandhi, RA Allden, JP Bleasdale, EN Fogden, MR Anderson and P Sen Gupta. Efficacy, safety, tolerability and sustainability outcomes of endoscopic proximal intestinal exclusion with Endobarrier: 1st UK NHS Endobarrier service for diabesity. Diabetologia 2017, Vol.60 Supplement1: Abstract 701.
Abstract: https://www.easd.org/media-centre/home.html#!resources/efficacy-safety-…
ePoster: https://www.easd.org/media-centre/home.html#!resources/efficacy-safety-…
BSG 2017 M Anderson, PSen Gupta, M Yadagiri, S Irwin, W Burbridge, N Taylor, R Allden, M Wilson, H Gandhi, J Bleasdale, R Ryder, E Fogden. Efficacy, safety and tolerability outcomes of endoscopic proximal intestinal exclusion using endobarrier, 12 and 18 month data for the uk’s first nhs endobarrier service for diabesity. British Society of GastroEnterology abstract published in Gut 2017;66:
http://dx.doi.org/10.1136/gutjnl-2017-314472.1.
ABCD Autumn 2017 M Yadagiri, N Ashman, J Adams, F Kinney, M Lang, JP Bleasdale, EN Fogden, MR Anderson, M Greenstone, C Walton, REJ Ryder. Seven out of the first eight patients in the ABCD EndoBarrier® in obstructive sleep apnoea(End-OSA) study no longer require continuous positive airway pressure ventilation(CPAP) after 3 months treatment with EndoBarrier. Oral presentation, ABCD Autumn Meeting 2017.
https://abcd.care/resource/seven-out-first-eight-patients-abcd-endobarr…
DUK Glasgow 2016 P Sen Gupta, VS Johal, BM McGowan, RS Drummond, SA Amiel and REJ Ryder. Early (6 month) metabolic and body weight effects of duodenal exclusion with endobarrier as an adjunct to glucagon-likepeptide-1 (GLP-1) therapy in sub optimally controlled Type 2 diabetes. Diabetic Medicine 2016. 33 (Suppl 1): Abstract A26.
https://doi.org/10.1111/dme.4_13047
ENDO 2016 Piya Sen Gupta, Barbara MC McGowan, Stephanie A Amiel, Robert EJ Ryder, Sebastian T Lugg , Russell S Drummond. One Year Efficacy, Safety and Tolerability Outcomes of Endoscopic Duodenal Exclusion Using Endobarrier as an Adjunct to Glucagon-like Peptide-1 (GLP-1) Therapy in Suboptimally Controlled Type 2 Diabetes: A Randomised Controlled Trial. Proceedings of ENDO Conference, Boston, USA, April 2016.
https://abcd.care/resource/endo2016
DDW 2016 E Fogden, P Sen Gupta, M Anderson, B Hayee, RS Drummond, BM McGowan, SA Amiel, REJ Ryder. One Year Efficacy, Safety and Tolerability Outcomes of Endoscopic Duodenal Exclusion using Endobarrier as an Adjunct to Glucagon-like Peptide-1 (GLP-1) therapy in Suboptimally Controlled Type 2 Diabetes: a Randomised Controlled Trial. Proceedings of the Digestive Diseases Week (DDW), San Diego, USA May 2016.
https://abcd.care/resource/fogden-ddw-2016-endobarrier
DDW 2016 Hayee B, Sen Gupta P, Anderson M, Fogden E, Roy AA, Butler DB, Bajwa RS, Amiel SA, Ryder REJ. Endoscopic proximal intestinal exclusion can improve non-alcoholic fatty liver disease (NAFLD) in patients with diabesity. Proceedings of the Digestive Diseases Week (DDW), San Diego, May 2016.
https://abcd.care/resource/hayee-ddw-2016-endobarrier
ESGAR 2016 V. Hedayati, P. Sen Gupta, B.M. McGowan, R.E. Ryder, F. Rubino, S.A. Amiel, S.M. Ryan. Contrast-enhanced computed tomography (CT) assessment of the positioning of a novel intestinal bypass liner device (Endobarrier) for type 2 diabetes: correlation of the degree of metabolic response with the extent of intestinal exclusion. Proceedings of the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), Prague, June 2016. ESGAR 2016 Book of Abstracts. Insights Imaging 7 (Suppl 2), 557–610 (2016).
https://doi.org/10.1007/s13244-016-0502-9
ADA New Orleans 2016 Robert E.J. Ryder, Vikramdeep S. Johal, Holly M. Murphy, Zoe S. Littlewood, Russell S. Drummond, Barbara M. McGowan, Stephanie A. Amiel, Piya Sen Gupta. The Effect of 1-Year’s Endoscopic Proximal Intestinal Exclusion Using Endobarrier on 10-Year Cardiovascular Risk in Type 2 Diabetes. Diabetes 2016 Jul; 65 (Supplement 1): 263-OR.
http://app.core-apps.com/tristar_ada16/abstract/92b0eac0f984437a5bebc08…
EASD Munich 2016 P Sen Gupta, RS Drummond, BM McGowan, SA Amiel, REJ Ryder. One year efficacy, safety and tolerability of duodenal exclusion using Endobarrier as an adjunct to glucagon-like-peptide-1 (GLP-1) therapy: a randomised controlled trial. Diabetologia 2016, Vol.59 Supplement1: Abstract 569.
Posters
ADA 2023 (Poster)
ADA 2023 (ePoster)
ADA 2022a (ePoster)
ADA 2022b (ePoster)
ADA 2021 (ePoster)
ADA 2020a (ePoster)
ADA 2020b (ePoster)
ADA 2019a (ePoster)
ADA 2019b (ePoster)
ADA 2018a (ePoster)
ADA 2018b (ePoster)
ADA 2018c (ePoster)
ADA 2018d (ePoster)
ADA 2017 (ePoster)
EASD 2023
EASD 2020 REJR
EASD 2020 MY
EASD 2019
EASD 2018
EASD 2017a
EASD 2017b
EASD 2016
DUK 2024
DUK 2023
DUK 2021
DUK 2020a
DUK 2020b
DUK 2020c
DUK 2019a
DUK 2019b
DUK 2018a
DUK 2018b
DUK 2018c
DUK 2017a
DUK 2017b
DUK 2017c
WCITD 2019a
WCITD 2019b
WCITD 2019c
WCITD 2019d
